SHR-1819
- Generic Name
- SHR-1819
Efficacy and Safety Study of SHR-1819 Injection in Adult Patients With Severe Atopic Dermatitis
Phase 3
Recruiting
- Conditions
- Moderate to Severe Atopic Dermatitis
- Interventions
- Drug: Placebo
- First Posted Date
- 2024-06-21
- Last Posted Date
- 2025-03-10
- Lead Sponsor
- Guangdong Hengrui Pharmaceutical Co., Ltd
- Target Recruit Count
- 650
- Registration Number
- NCT06468956
- Locations
- 🇨🇳
Shanghai Fudan University HuaShan Hospital, Shanghai, Shanghai, China
Efficacy and Safety Study of SHR-1819 Injection in Adult Patients With Severe Atopic Dermatitis
Phase 2
Completed
- Conditions
- Moderate to Severe Atopic Dermatitis
- Interventions
- Drug: Placebo
- First Posted Date
- 2022-09-22
- Last Posted Date
- 2024-01-23
- Lead Sponsor
- Shanghai Hengrui Pharmaceutical Co., Ltd.
- Target Recruit Count
- 158
- Registration Number
- NCT05549947
- Locations
- 🇨🇳
Huashan Sub-Hospital of Fudan University, Shanghai, Shanghai, China
A Phase 1, Randomized, Double-blind, Placebo-controlled, Single and Multiple Dose Escalation Study in Healthy Subjects
- First Posted Date
- 2021-02-26
- Last Posted Date
- 2022-11-29
- Lead Sponsor
- Shanghai Hengrui Pharmaceutical Co., Ltd.
- Target Recruit Count
- 52
- Registration Number
- NCT04772365
- Locations
- 🇨🇳
The Third Xiangya Hospital of Central South University, Changsha, Changsha, China
A Trial of SHR-1819 in Healthy Subjects
- First Posted Date
- 2020-09-23
- Last Posted Date
- 2022-07-12
- Lead Sponsor
- Atridia Pty Ltd.
- Target Recruit Count
- 42
- Registration Number
- NCT04561128
- Locations
- 🇦🇺
Atridia Pty Limited, Sydney, New South Wales, Australia
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2025. All Rights Reserved by MedPath